LivaNova (NASDAQ:LIVN) Stock Price Target Raised at Needham & Company LLC

LivaNova (NASDAQ:LIVN) had its target price lifted by Needham & Company LLC from $93.00 to $112.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other brokerages have also recently issued reports on LIVN. Mizuho raised their target price on shares of LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Weiss Ratings upgraded LivaNova from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, October 27th. Stifel Nicolaus set a $85.00 target price on LivaNova in a research report on Wednesday, August 5th. Barclays raised shares of LivaNova to a “strong-buy” rating in a research note on Wednesday, October 7th. Finally, Zacks Research downgraded LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.67.

LivaNova Stock Up 17.9%

LIVN stock opened at $94.19 on Wednesday. The business has a 50 day moving average of $78.85 and a 200 day moving average of $73.25. The company has a quick ratio of 1.21, a current ratio of 1.45 and a debt-to-equity ratio of 0.22. The firm has a market cap of $5.19 billion, a PE ratio of 22.26 and a beta of 0.91. LivaNova has a twelve month low of $48.82 and a twelve month high of $99.38.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.06 by $0.17. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The company had revenue of $393.15 million for the quarter, compared to the consensus estimate of $381.13 million. During the same period in the prior year, the firm posted $1.11 EPS. LivaNova’s revenue for the quarter was up 9.9% on a year-over-year basis. On average, research analysts forecast that LivaNova will post 3.78 EPS for the current fiscal year.

Insider Activity

In other news, Director Francesco Bianchi sold 3,500 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the sale, the director directly owned 4,434 shares in the company, valued at $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Brooke Story sold 2,300 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director directly owned 7,488 shares of the company’s stock, valued at approximately $609,672.96. The trade was a 23.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 7,450 shares of company stock valued at $591,839. Corporate insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in LivaNova by 2.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company’s stock valued at $116,067,000 after acquiring an additional 38,320 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of LivaNova by 1,978.8% during the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after purchasing an additional 448,703 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of LivaNova during the 1st quarter worth approximately $18,327,000. Sei Investments Co. boosted its holdings in shares of LivaNova by 56.6% during the 1st quarter. Sei Investments Co. now owns 218,805 shares of the company’s stock worth $13,907,000 after purchasing an additional 79,088 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of LivaNova by 15.7% in the first quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock valued at $11,631,000 after purchasing an additional 24,900 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova News Summary

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q3 results beat estimates: LivaNova reported adjusted earnings of $1.23 per share, above analyst expectations, while revenue of $393.15 million rose 9.9% year over year and topped forecasts. Earnings results
• Positive Sentiment: Higher 2026 earnings guidance: The company raised its full-year EPS outlook to $4.40–$4.50 and forecast revenue growth of 9%–10%, signaling confidence in continued performance. 2026 outlook
• Positive Sentiment: Analyst target raised: Needham lifted its price target from $93 to $112 and maintained a Buy rating, reflecting a more favorable view of the shares’ prospects.
• Positive Sentiment: Potential new growth avenue: LivaNova is looking at entering neuromodulation for obstructive sleep apnea (OSA), a potential market opportunity beyond its current businesses. OSA neuromodulation opportunity

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company’s Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.